Multicenter, randomized clinical trials, such as IMbrave 150 and Orient 32, have been demonstrated the effectiveness of programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor based anti-PD-1/PD-L1 therapy in HCC patients (2–6). This evidence concerns the gene CD274 and hepatocellular carcinoma.